Overview

Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia

Status:
Completed
Trial end date:
2020-02-13
Target enrollment:
Participant gender:
Summary
Leucine-rich glioma inactivated 3(Lgi3) has been postulated to have a pro-inflammatory adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation according to recent investigations. Thus, in this study, we sought to demonstrate that the treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to further evaluate the role of Lgi3 in atherosclerosis.
Phase:
N/A
Details
Lead Sponsor:
Yonsei University
Treatments:
Pitavastatin